Dyne Therapeutics announced positive clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy (DMD). The drug showed significant dystrophin expression and functional improvements in patients, exceeding levels observed in other DMD treatments. Dyne plans to initiate registrational cohorts in the trial and provide an update on the path to registration by the end of 2024.
U.S. stock futures opened lower on Tuesday, with the Nasdaq futures leading the decline. Dyne Therapeutics shares fell sharply after positive clinical trial data, while other notable pre-market losers included Acadia Healthcare, United States Steel, Diversified Energy, and LG Display. Several factors, including potential strikes and downgraded ratings, contributed to the downward trend in some stocks.
